Premium
First annual report of Chinese haemovigilance network
Author(s) -
Yin Yonghua,
Tian Xue,
Li Ling,
Kong Yujie,
Wang Jue,
Lin Feng,
Song Ning,
Chen Qiang,
Gan Jia,
Peng Tao,
Li Xiying,
Wu Yanyun,
Ge Hongwei,
Wang Hongjie,
Jiang Jingmei,
Bai Lianjun,
Ji Hongwen,
Zhao Guohua,
Huang Yuguang,
Liu Zhong
Publication year - 2021
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.13059
Subject(s) - medicine , adverse effect , blood component , allergic reaction , blood transfusion , pediatrics , intensive care medicine , immunology , allergy
Background and objectives Haemovigilance involves surveillance of the whole chain of blood transfusion with the aim of identifying adverse events and errors and improving outcomes for patients. The Chinese Haemovigilance Network, founded in August 2017, has witnessed a rapid development in the last three years. Materials and methods Based on the 1,022 cases in 2019, we analysed the adverse reactions (ARs) by blood component, clinical outcome severity and demography of recipients in an effort to publish the first annual Chinese haemovigilance report. Results The AR rate associated with blood transfusion in 2019 was 0·2% in China. Allergic reactions and FNHTR were the two most common adverse symptoms, accounting for 97·7% of the reports. Two‐thirds of the TAD, AHTR and TACO and all of the HTR and DHTR resulted in hospitalization or prolongation of hospitalization. Plasma and AP were usually associated with allergic reaction (81·1%), whereas red cells more commonly cause FNHTR (68·8%) and all the AHTR, HTR, DSTR and DHTR. 84·1% of patients were aged 16 years or over, and the majority of the TAD, AHTR, TACO and HTR involved patients aged 60 and above. The ratio of serious adverse reactions (SARs) was 8·2%. Allergic reaction and FNHTR were top two (85·7%) SARs. The first case related to anti‐D immunoglobulin was detected in a DHTR report. Conclusion This report provides the world’s first overview of transfusion‐related adverse reactions in China. This report is useful for better understanding transfusion risks in China.